.png)
%20(1).png)
.png)
.png)
Reg CF vs Reg D 506(c) vs Reg A+
We support compliant investor acquisition for Reg CF, Reg D 506(c), and Reg A+, with Reg D 506(c) typically best for diligence‑heavy biotech raises with larger checks, Reg CF for smaller, more understandable offerings, and Reg A+ for larger raises that require broad marketing and higher ongoing reporting.
| Feature | Reg CF | Reg D 506(c) | Reg A+ |
|---|---|---|---|
| Best For | Smaller, story‑driven biotech raises with clear, simple narratives. | Larger biotech rounds from accredited investors needing deep diligence.Bigger biotech platforms needing broad, public‑style marketing. | Bigger biotech platforms needing broad, public‑style marketing. |
| Typical Raise Size | $100K–$5M | $500K–$20M+ | $5M–$75M+ |
| Investor Type | Retail + accredited | Accredited only | Retail + accredited |
| Marketing Scope | Broad, compliant | Accredited-focused outreach | Broadest public-style marketing |
| Timeline | 6–12 weeks | 8–16 weeks | 12–20+ weeks |
| Timeline | Early data generation, core IP work, and initial milestones. | Advancing clinical programs, expanding indications, and scaling ops. | Multi‑program platforms, later‑stage trials, and global expansion. |
We coordinate with your counsel on structure and disclosures and do not provide legal advice or guarantees.
Why BioTech Software Fundraising Is Different
Biotech investors underwrite milestones. If you cannot articulate the clinical path, indication strategy, IP position, and what each dollar achieves, your investor interest will not convert.
Scientific Validity & Differentiation
Mechanism, data quality, reproducibility, and what truly differentiates the approach.
IP Defensibility
Composition, method, and freedom‑to‑operate considerations that support a durable moat.
Indication Strategy & Competition
Choice of indications, sequencing, and positioning against current and emerging competitors.
Clinical & Regulatory Pathway
Trial phases, endpoints, timelines, regulatory strategy, and key risk points.
Capital Efficiency & Milestones
What each tranche of capital achieves in terms of data, endpoints, and inflection events.
Evidence‑Based Story & Use of Proceeds
Clear separation between what is proven vs hypothesis and capital tied to milestone‑based use of proceeds.
Generic fundraising messaging fails here. We build investor acquisition systems that reflect how investors actually evaluate risk and upside in this category.
Who We Work With
Strong Fit
We work best with BioTech software teams that:
- You have credible data or validation signals (preclinical, clinical, published, or partnered).
- You can clearly articulate milestones, endpoints, and timeline assumptions.
- Your IP strategy and differentiation are coherent and defensible.
- No credible evidence plan and no validation timeline.
Not a Fit
We are not the right partner for:
- No traction and no credible plan to validate quickly.
- Overstated claims not supported by data.
- Looking for guaranteed fundraising outcomes.
- Unwilling to maintain disciplined disclosure and compliance.
Investor Acquisition System
A complete system for SaaS & B2B Software to acquire investors
Capital Strategy & Investor Positioning
Goal Alignment: We set clear, measurable objectives from the start
Incentive-Based Fees: Our earnings are tied to the results we deliver.
Ongoing Optimization: We continuously refine strategies to maximize ROI.
We align the raise structure to your stage and evidence, then build investor positioning around milestones, differentiation, and capital efficiency.
Goal Alignment
Incentive-Based Fees
Ongoing Optimization
Compliant Funnel & Conversion Architecture
We design funnels that qualify seriousness and educate investors, ensuring conversations are diligence‑ready.
Custom Audiences
Lookalike Modeling
Interest Filtering
Goal Alignment: We set clear, measurable objectives from the start
Incentive-Based Fees: Our earnings are tied to the results we deliver.
Ongoing Optimization: We continuously refine strategies to maximize ROI.
Investor Traffic & Outreach
We deploy targeted acquisition to reach accredited investors and biotech‑aligned profiles based on raise type and thesis fit.
Regulatory Review
Conversion Focused
Brand Aligned
Goal Alignment: We set clear, measurable objectives from the start
Incentive-Based Fees: Our earnings are tied to the results we deliver.
Ongoing Optimization: We continuously refine strategies to maximize ROI.
Retail investors aligned with consumer brands
Accredited investors interested in cash-flowing and asset-backed opportunities
Repeat investors with prior alternative investment experience
Investor Nurture & Engagement
We implement sequences that address common biotech questions—data, IP, indication, pathway, and risk—before calls happen.
Real-Time Tracking
A/B Testing
Cost Optimization
Goal Alignment: We set clear, measurable objectives from the start
Incentive-Based Fees: Our earnings are tied to the results we deliver.
Ongoing Optimization: We continuously refine strategies to maximize ROI.
Reporting, Optimization & Raise Support
You receive full visibility into lead quality, engagement, and conversion across the funnel.
Intent Scoring
Behavior Analysis
Clean Pipeline
Goal Alignment: We set clear, measurable objectives from the start
Incentive-Based Fees: Our earnings are tied to the results we deliver.
Ongoing Optimization: We continuously refine strategies to maximize ROI.
Optimization & Raise Guidance
We optimize based on real commitment signals and keep your investor acquisition strategy aligned with milestone progress.
Weekly Reports
Direct Access
Strategic Guidance
Goal Alignment: We set clear, measurable objectives from the start
Incentive-Based Fees: Our earnings are tied to the results we deliver.
Ongoing Optimization: We continuously refine strategies to maximize ROI.
Free Strategy Session
Ready to Raise SaaS & B2B Capital
Predictably?
If you’re serious about raising SaaS & B2B capital—and you want a structured, compliant approach that investors respect—the next step is simple.
Only 3 consultation slots left this week
No obligation
15-minute call
Actionable insights
Frequently Asked Questions
What do biotech investors care about most?
Investors typically prioritize data quality, differentiation, IP defensibility, indication strategy, clinical pathway, and milestone‑based capital efficiency.
How do you market biotech without making unsupported claims?
We build claims‑safe positioning that clearly separates what is proven from what is planned, and we emphasize milestones and evidence without overpromising.
Is Reg D 506(c) usually the best fit for biotech?
Often yes due to diligence intensity and larger check sizes. Reg CF can work for smaller raises when the story is easier for retail investors to understand.
How long does it take to launch investor acquisition?
Most campaigns take 6–14 weeks depending on offering type, funnel build, and creative requirements.
Do you guarantee fundraising results?
No. We provide the investor acquisition system—not a guarantee of capital raised.
.png)
Growth Turbine is a performance-driven equity crowdfunding, investor acquisition and offering marketing agency. We help issuers build compliant investor acquisition infrastructure—positioning, funnels, paid media, and investor-relations reporting—across Reg CF, Rule 506(c), Reg A+, private funds, and regulated digital securities.
.svg){kind=icon}
.svg){kind=small}